Arvee Laboratories (India) Ltd
₹ 177
-4.20%
24 Jul
- close price
About
Incorporated in 2012, Arvee Laboratories India Ltd manufactures specialized chemicals[1]
Key Points
- Market Cap ₹ 195 Cr.
- Current Price ₹ 177
- High / Low ₹ 315 / 104
- Stock P/E 186
- Book Value ₹ 26.4
- Dividend Yield 0.00 %
- ROCE 7.03 %
- ROE 3.67 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
Cons
- Stock is trading at 6.71 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of -11.2% over past five years.
- Company has a low return on equity of 9.89% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|
26.82 | 34.44 | 47.78 | 54.90 | 45.42 | 47.38 | 40.33 | 61.35 | 30.35 | |
21.83 | 28.54 | 40.61 | 48.73 | 39.40 | 41.31 | 34.65 | 54.06 | 27.35 | |
Operating Profit | 4.99 | 5.90 | 7.17 | 6.17 | 6.02 | 6.07 | 5.68 | 7.29 | 3.00 |
OPM % | 18.61% | 17.13% | 15.01% | 11.24% | 13.25% | 12.81% | 14.08% | 11.88% | 9.88% |
0.10 | 0.51 | 0.23 | 0.35 | 0.35 | 0.56 | 0.46 | 1.35 | 0.58 | |
Interest | 3.07 | 3.48 | 3.33 | 1.63 | 0.99 | 0.58 | 0.37 | 0.39 | 0.25 |
Depreciation | 1.49 | 2.07 | 2.15 | 2.35 | 2.29 | 2.41 | 2.32 | 2.08 | 1.50 |
Profit before tax | 0.53 | 0.86 | 1.92 | 2.54 | 3.09 | 3.64 | 3.45 | 6.17 | 1.83 |
Tax % | 66.04% | -81.40% | 43.23% | 11.02% | 25.89% | 26.37% | 25.51% | 33.23% | 42.62% |
0.19 | 1.55 | 1.09 | 2.26 | 2.30 | 2.68 | 2.57 | 4.12 | 1.05 | |
EPS in Rs | 0.23 | 1.91 | 0.99 | 2.05 | 2.09 | 2.43 | 2.33 | 3.74 | 0.95 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | -11% |
3 Years: | -14% |
TTM: | -51% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | -14% |
3 Years: | -25% |
TTM: | -74% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 45% |
3 Years: | 17% |
1 Year: | 54% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 11% |
3 Years: | 10% |
Last Year: | 4% |
Balance Sheet
Figures in Rs. Crores
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|
Equity Capital | 4.05 | 4.05 | 5.51 | 5.51 | 5.51 | 11.02 | 11.02 | 11.02 | 11.02 |
Reserves | -1.41 | 0.15 | 8.69 | 10.95 | 13.25 | 10.42 | 12.92 | 17.04 | 18.09 |
25.32 | 24.99 | 16.15 | 12.87 | 3.87 | 8.88 | 3.13 | 1.00 | 1.00 | |
7.25 | 6.49 | 13.77 | 7.81 | 11.00 | 10.73 | 11.61 | 9.63 | 8.45 | |
Total Liabilities | 35.21 | 35.68 | 44.12 | 37.14 | 33.63 | 41.05 | 38.68 | 38.69 | 38.56 |
13.15 | 16.88 | 14.88 | 12.65 | 13.18 | 13.81 | 13.84 | 12.68 | 12.68 | |
CWIP | 4.30 | 0.00 | 1.18 | 2.32 | 1.78 | 0.97 | 0.98 | 1.53 | 2.62 |
Investments | 0.00 | 0.00 | 0.00 | 1.95 | 3.09 | 2.03 | 0.00 | 0.00 | 0.00 |
17.76 | 18.80 | 28.06 | 20.22 | 15.58 | 24.24 | 23.86 | 24.48 | 23.26 | |
Total Assets | 35.21 | 35.68 | 44.12 | 37.14 | 33.63 | 41.05 | 38.68 | 38.69 | 38.56 |
Cash Flows
Figures in Rs. Crores
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|
4.03 | 6.02 | 9.46 | 10.31 | 1.71 | 0.68 | 2.93 | 6.71 | ||
-1.40 | -1.23 | -2.85 | -3.08 | -0.60 | 0.06 | -1.26 | -5.15 | ||
-2.92 | -3.78 | -4.92 | -9.90 | 4.52 | -6.06 | -2.42 | -0.25 | ||
Net Cash Flow | -0.29 | 1.00 | 1.68 | -2.67 | 5.63 | -5.32 | -0.75 | 1.31 |
Ratios
Figures in Rs. Crores
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|
Debtor Days | 82.61 | 87.12 | 118.25 | 52.66 | 52.40 | 60.70 | 109.78 | 72.94 | 73.48 |
Inventory Days | 155.08 | 104.53 | 99.61 | 42.90 | 80.96 | 91.96 | 93.24 | 42.29 | 157.84 |
Days Payable | 130.73 | 98.14 | 150.03 | 55.84 | 125.63 | 118.08 | 160.12 | 73.30 | 163.26 |
Cash Conversion Cycle | 106.96 | 93.50 | 67.84 | 39.72 | 7.72 | 34.59 | 42.90 | 41.94 | 68.06 |
Working Capital Days | 115.54 | 107.57 | 82.73 | 44.88 | 25.64 | 50.07 | 69.24 | 70.44 | 94.41 |
ROCE % | 15.19% | 17.64% | 13.67% | 14.90% | 14.92% | 12.89% | 23.34% | 7.03% |
Documents
Announcements
-
Trading Window
29 June 2024 - Arvee Laboratories (India) Limited has informed regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
-
Appointment
24 June 2024 - Arvee Laboratories (India) Limited has informed regarding Appointment of Mr Praveenkuma as Non- Executive Director of the company w.e.f. Jun 24, 2024.
-
Updates
21 May 2024 - Arvee Laboratories (India) Limited has informed regarding 'outcome of Board Meeting as per attachment. '.
-
Outcome of Board Meeting
17 May 2024 - Arvee Laboratories (India) Limited has informed regarding Board meeting held on May 17, 2024.
-
Financial Result Updates
17 May 2024 - Arvee Laboratories (India) Limited has submitted to the Exchange, the financial results for the period ended March 31, 2024.
Product Profile:
a) Polymer Modifiers:[1]
Dimethyl 5-Sodiosulfoisophthalate, 5-Sulfoisophthalic Acid Mono Sodium Salt, 5-Sulfoisophthalic Acid Mono Lithium Salt, 5-Sodiosulfo-Bis-(β-Hydroxyethyl)-Isophthalate
b) Contrast Media Intermediates:[2]
5-Nitroisophthalic acid, Dimethyl 5-Nitroisophthalate, Monomethyl 5-Nitroisophthalate, 5-Hydroxyisophthalic
acid, 5-Aminoisophthalic acid, Dimethyl
5-Aminoisophthalate, 3,5-Dinitrobenzoic
Acid, 3,5-Diamino Benzoic Acid
c) Drug Intermediates:[3]
2-Acetyl Thiophene, Thiophene-2-Carboxaldehyde, Amino Pyridine,
Chloro Nitrobenzoic Acid